SCHEDULE: Royce & Associates LP Discloses 4.27% Stake in OptimizeRx Corp

Royce & Associates LP, an investment adviser, has filed an amended Schedule 13G disclosing a 4.27% beneficial ownership stake in OptimizeRx Corp.

Summary

• Royce & Associates LP, a New York-based investment adviser, reported beneficial ownership of 790,640 shares of OptimizeRx Corp's Common Stock.
• This ownership represents 4.27% of the class of securities.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported stake.
• Royce & Associates LP holds sole voting power and sole dispositive power over all 790,640 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of OptimizeRx Corp.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, with no positive or negative operational or financial information about the issuer.

Risks

• Royce & Associates LP disclaims any pecuniary interest in the reported securities.
• The filing should not be construed as an admission that Royce & Associates LP is the beneficial owner, as defined in Rule 13d-3, of any such securities.
• Royce & Associates LP believes it is not a 'group' with Franklin Resources, Inc. affiliates or the Principal Shareholders (Charles B. Johnson and Rupert H. Johnson, Jr.) within the meaning of Rule 13d-5 under the Act.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect."

Industry Context

This filing is a routine disclosure of an institutional investor's passive ownership stake, common within the financial industry for transparency regarding significant holdings in publicly traded companies. It does not provide insights into broader industry trends or competitive dynamics beyond the fact that OptimizeRx Corp is a publicly traded entity attracting institutional investment.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, confirming a passive investment approach by Royce & Associates LP.

Key Dates

Keywords

OptimizeRx Corp, Royce & Associates LP, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Shareholding, Institutional Investor